Healthcare / Medical DevicesShenzhen
$17.46
-0.35 (-1.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $43.5M · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.2B
P/E
N/A
•EV/EBITDA
47.8x
↑ROE
-1.2%
↓Gross Margin
57.0%
↑Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-28.4%
FCF CAGR
-47.6%
FCF margin
7.6%
FCF / Net income
-2.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.09B · net income $-63.0M · FCF $158.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.09B | $2.09B | $3.06B | $2.76B | $5.68B |
| Net Income | $-63.0M | $-63.0M | $561.6M | $487.6M | $1.20B |
| EBITDA | $179.9M | $179.9M | $932.2M | $847.8M | $1.67B |
| EPS | -0.13 | -0.13 | 1.21 | 1.10 | 2.71 |
| Gross Margin | 57.0% | 57.0% | 64.1% | 62.6% | 51.8% |
| Operating Margin | -4.7% | -4.7% | 21.5% | 18.4% | 24.7% |
| Net Margin | -3.0% | -3.0% | 18.3% | 17.6% | 21.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.11 | 0.11 | 0.11 | 0.13 | 0.18 |
| Current Ratio | 3.22 | 3.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $158.5M | $158.5M | $43.5M | $-104.1M | $1.10B |
| Returns | |||||
| ROE | -1.2% | -1.2% | 10.1% | 10.8% | 27.6% |
| Valuation | |||||
| P/E | — | — | 17.82 | 27.33 | 11.70 |
| EV/EBITDA | 47.82 | 47.82 | 10.48 | 15.43 | 8.17 |
| P/B | 1.56 | 1.56 | 1.80 | 2.95 | 3.23 |
| Growth & Yield | |||||
| Revenue Growth | -31.9% | -31.9% | 10.8% | -51.3% | — |
| EPS Growth | -110.7% | -110.7% | 10.0% | -59.4% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.1%
Start / end P/E
n/dx → n/dx
EPS bridge
1.21 → -0.13
Residual
-18.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.